发明名称 |
Treatment of neurodegenerative diseases by targeting miRNA |
摘要 |
The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases by targeting a specific miRNA. In addition, the present invention relates to a kit for diagnosing neurodegenerative diseases. A miR-206 target found in the present invention, which is highly expressed in both animal models of Alzheimer's disease and human brain samples, is a substantial treatment target selected without artifact errors. An antisense oligonucleotide of the present invention as an inhibitor for miR-206 suggests a successful result in treatment of neurodegenerative diseases by targeting miRNA. The antisense oligonucleotide of the present invention inhibits the function of miR-206 to greatly increase the levels of BDNF and IGF-1 and to increase the regeneration of synapses, thereby treating neurodegenerative diseases, particularly Alzheimer's disease. |
申请公布号 |
US9301969(B2) |
申请公布日期 |
2016.04.05 |
申请号 |
US201113822641 |
申请日期 |
2011.09.09 |
申请人 |
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
发明人 |
Roh Jae-Kyu;Lee Sang Kun;Kim Man Ho;Chu Kon;Jung Keun-Hwa;Lee Soon-Tae |
分类号 |
A61K31/7088;A61K31/7105;A61K31/711;C12Q1/68 |
主分类号 |
A61K31/7088 |
代理机构 |
Harness, Dickey & Pierce, P.L.C. |
代理人 |
Harness, Dickey & Pierce, P.L.C. |
主权项 |
1. A method for treating an Alzheimer's disease, comprising administering to a subject in need thereof a pharmaceutical composition comprising:
(a) a pharmaceutically effective amount of an antisense oligonucleotide having perfect complementarity to SEQ ID NO:1; and (b) a pharmaceutically acceptable carrier, wherein the antisense oligonucleotide is a 2′—O—C1-3 alkyl ribonucleotide. |
地址 |
Seoul KR |